I read the article and the 2012 10-K. Their infectious disease programs is almost fully funded by the gov't and DoD. If they have $110mil net cash on hand. They are basically covered when it comes to DMD. Now, I don't know about you but this looks like the guy that wrote this didn't factor in how gov't plays a funding role. It's not like SRPT is flapping in the wind.
I take it as a worst case scenario type of planning - better to have too much cash than too little. It wouldn't be a bad way to go I would never trust this administration to make good on its funding promises until the cash is in the hands. That money could be better spent propping up the DOW, you know, instead of using it to help people.
Amazing what some people will do for a penny a page-hit. Read the article and it says nothing new and works from the underlying assumption that AA will not happen so they (SRPT) might as well borrow while AA is still on the table. Of course that ignores the fact that the FDA's RFI was actually a POSITIVE insofar as the potential for AA is concerned. Go figure.
I think he slapped something together on SRPT so he could gain more exposure about that second stock he talked about Med Biogene. Not a dumb strategy really. Put some offensive title, talk about a stock like SRPT where you know you're gonna get a lot of people's blood in a rush, then at the end "oh ya MBI is an example of a good partnership deal, SRPT is an example of a good finance and go at it yourself type of deal. Go buy MBI along with your SRPT".